PMID- 24361264 OWN - NLM STAT- MEDLINE DCOM- 20141101 LR - 20141120 IS - 1872-8111 (Electronic) IS - 0168-0102 (Linking) VI - 79 DP - 2014 Feb TI - Involvement of Wnt/beta-catenin signaling in the development of neuropathic pain. PG - 34-40 LID - S0168-0102(13)00265-4 [pii] LID - 10.1016/j.neures.2013.12.002 [doi] AB - Despite tremendous research effort in the field, our current understanding of the molecular mechanisms underlying neuropathic pain is still incomplete. In the present study, our objective was to elucidate the involvement of the Wnt/beta-catenin signaling pathway in the development of neuropathic pain. We showed that Wnt/beta-catenin signaling is activated in the spinal cord dorsal horn after partial sciatic nerve ligation (PSL). Expression of Wnt3a, a prototypic Wnt ligand that activates the Wnt/beta-catenin pathway, was also upregulated in the dorsal horn. We then tested the effect of intrathecal administration of XAV939, a Wnt/beta-catenin signaling inhibitor, and found that this treatment effectively attenuated the induction of neuropathic pain. Conversely, intrathecal administration of Wnt3a to the lumbar spinal cord of naive animals triggered the development of allodynia. These results suggest a critical involvement of the Wnt/beta-catenin pathway in the development of neuropathic pain. Moreover, we also found that PSL-induced microglial activation was significantly suppressed by intrathecal administration of XAV939 treatment. Because it was revealed that Wnt3a treatment triggered brain-derived neurotrophic factor (BDNF) release from microglial cells in vitro, it is possible that Wnt3a upregulation in the dorsal horn leads to the activation of microglial cells, then triggers BDNF secretion that is responsible for the establishment of neuropathic pain. Further studies will be needed for the comprehensive understanding of the roles of Wnt/beta-catenin signaling in the development of neuropathic pain. CI - Copyright (c) 2013 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved. FAU - Itokazu, Takahide AU - Itokazu T AD - Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Department of Neurology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. FAU - Hayano, Yasufumi AU - Hayano Y AD - Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. FAU - Takahashi, Ryosuke AU - Takahashi R AD - Department of Neurology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. FAU - Yamashita, Toshihide AU - Yamashita T AD - Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: yamashita@molneu.med.osaka-u.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131217 PL - Ireland TA - Neurosci Res JT - Neuroscience research JID - 8500749 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (CTNNB1 protein, mouse) RN - 0 (Wnt3 Protein) RN - 0 (Wnt3 protein, mouse) RN - 0 (beta Catenin) SB - IM MH - Animals MH - Brain-Derived Neurotrophic Factor/analysis MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Microglia/metabolism MH - Neuralgia/*metabolism MH - Rats MH - Rats, Wistar MH - Spinal Cord/*metabolism MH - Wnt Signaling Pathway/*physiology MH - Wnt3 Protein/metabolism MH - beta Catenin/metabolism OTO - NOTNLM OT - Brain-derived neurotrophic factor OT - Microglia OT - Neuropathic pain OT - Wnt signaling EDAT- 2013/12/24 06:00 MHDA- 2014/11/02 06:00 CRDT- 2013/12/24 06:00 PHST- 2013/10/23 00:00 [received] PHST- 2013/12/10 00:00 [revised] PHST- 2013/12/10 00:00 [accepted] PHST- 2013/12/24 06:00 [entrez] PHST- 2013/12/24 06:00 [pubmed] PHST- 2014/11/02 06:00 [medline] AID - S0168-0102(13)00265-4 [pii] AID - 10.1016/j.neures.2013.12.002 [doi] PST - ppublish SO - Neurosci Res. 2014 Feb;79:34-40. doi: 10.1016/j.neures.2013.12.002. Epub 2013 Dec 17.